Anti-Angiogenic Systemic Therapies for Advanced HCC in Second Line and Beyond : vimarsana.com

Expert panelists highlight anti-angiogenic systemic therapies under investigation for advanced HCC in second line and beyond.

Related Keywords

, Transforming Outcomes , Hepatocellular Carcinoma , Expert Insights , Applying Evidence , Angiogenic Systemic Therapies , Second Line , Hcc , Intermediate Stage , Systemic Therapy , Bclc Stage B , Patient Selection , Locoregional , Tace , Liver Function , Tumor Board , Phase Iii Studies , Phase 3 Studies , Criteria , Unsuitable , Atezolizumab , Bevacizumab , Response , Pfs , Os , Liver Directed Therapy , Open Label Phase Ii , Japan , Regimen , Sorafenib , Optimis , High Afp ,